LONDON: Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider for the pharma and biotech industry, has announced significant progress in expanding its US commercial activities.

The company executed a commercial data partnership agreement in the first half of 2024 and four additional agreements in the second half, totaling £1.13 million ($1.48 million) in the first year. These partnerships are already contributing to revenue and Annual Recurring Revenue (ARR) growth for 2024.

The commercial data partnerships are designed to expand Diaceutics’ reach in the US through marketplaces and partner sales teams using a co-selling model. These contracts are expected to further scale the company’s reach by selling high-margin data products, like DXRX Signal, to a wider range of customers, including new segments and pharmaceutical brands.

Ryan Keeling, CEO of Diaceutics, expressed excitement about these new agreements, stating, “We are really excited by these new agreements and the ability to offer our DXRX platform to a much wider audience and, in the process, grow and scale our market opportunity. We are pleased to see these partnerships contributing revenue and ARR ahead of plan in 2024.”